Zai Lab Ltd
Close on Oct 19, 2026
- Market cap
- $26.87B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | Before market open | $106.30M | $-0.05 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | Before market open | $99.60M | $-0.05 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 26, 2026 | Before market open | $127.60M | $-0.05 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | Before market open | $116.10M | $-0.03 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | Before market open | $110.00M | – | $-0.04 |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | Before market open | $106.50M | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 27, 2025 | Before market open | $109.10M | $-0.08 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | Before market open | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 6, 2024 | After market close | $100.10M | $-0.08 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 8, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 27, 2024 | After market close | – | – | – |
Company guidance
Outlook given with results on Nov 6, 2025, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| total revenue | full year 2025 | $460.00M | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Zai Lab filed with the SEC
Zai Lab Announces Second Quarter 2026
Results of operations · EX-99.1 to Form 8-K
Zai Lab Announces First Quarter 2026
Results of operations · EX-99.1 to Form 8-K
Zai Lab Announces Fourth Quarter and Full Year 2025
Results of operations · EX-99.1 to Form 8-K
Zai Lab Announces Third Quarter 2025 Financial Results and Recent Corporate Updates
Results of operations · EX-99.1 to Form 8-K
Zai Lab Announces Second Quarter 2025 Financial Results and Recent Corporate Updates
Results of operations · EX-99 to Form 8-K
Zai Lab Announces First Quarter 2025 Financial Results and Recent Corporate Updates
Results of operations · EX-99.1 to Form 8-K
Zai Lab Announces Fourth Quarter and Full Year 2024
Results of operations · EX-99.1 to Form 8-K
Zai Lab Announces Pricing of Public Offering of American Depositary Shares
Material agreement · Other events · EX-99.1 to Form 8-K
Risks Related to Our Business and Industry
Other events · EX-99.1 to Form 8-K
Zai Lab Announces Third Quarter 2024
Results of operations · EX-99.1 to Form 8-K
Zai Lab Announces Second Quarter 2024
Results of operations · EX-99.1 to Form 8-K
Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases;
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Zai Lab Announces First Quarter 2024
Results of operations · EX-99.1 to Form 8-K
Zai Lab Announces Full-Year 2023
Results of operations · EX-99.1 to Form 8-K
Zai Lab Announces Third Quarter 2023
Results of operations · EX-99.1 to Form 8-K
Zai Lab Announces Second Quarter 2023
Results of operations · EX-99.1 to Form 8-K
Zai Lab Announces Promotion of Yajing Chen to Chief Financial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Zai Lab and argenx Announce Approval of VYVGART ® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China
Regulation FD disclosure · EX-99.1 to Form 8-K
Zai Lab Announces First Quarter 2023
Results of operations · EX-99.1 to Form 8-K
Zai Lab Announces Full-Year 2022 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Zai Lab and Novocure Announce Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint
Other events · EX-99.1 to Form 8-K
Zai Lab Announces Third Quarter 2022
Results of operations · EX-99.1 to Form 8-K
Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK ® (tisotumab vedotin-tftv)
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Zai Lab Announces Second Quarter 2022
Results of operations · EX-99.1 to Form 8-K
Zai Lab Announces First Quarter 2022
Results of operations · EX-99.1 to Form 8-K
Zai Lab Announces Financial Results and Corporate Updates for Twelve Months Ended December 31, 2021
Results of operations · EX-99.1 to Form 8-K
Zai Lab Announces NDA Acceptance of
Other events · EX-99.1 to Form 8-K
China NMPA Approves NUZYRA ® as a Category 1
Other events · EX-99.1 to Form 8-K
Zai Lab Announces Inclusion of ZEJULA ®
Other events · EX-99.1 to Form 8-K
Zai Lab and Blueprint Medicines Announce Strategic Collaboration and License
Material agreement · Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Zai Lab and Karuna Therapeutics Announce Strategic Collaboration for
Material agreement · Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Zai Lab Announces Third Quarter 2021
Material agreement · Results of operations · Regulation FD disclosure · EX-99.3 to Form 8-K
ZL-1102, Zai Lab’s Internally Developed Novel Human
Other events · EX-99.1 to Form 8-K
Zai Lab and Entasis Therapeutics Announce Positive
Other events · EX-99.1 to Form 8-K